This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
GI Dynamics, Inc. (ASX: GID) today announced that
The Sheba Medical Center (Tel Hashomer) at Ramat-Gan, Israel, is now offering
EndoBarrier® Therapy, a non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity. The Center is the first in the country to treat patients with this revolutionary medical device that helps reduce blood sugar and body weight at the same.
“Our diabetes center is at the forefront of innovative advances in managing type 2 diabetes and obesity, and we are pleased to offer EndoBarrier Therapy to our patients,” said Gabriella Lieberman, M.D., endocrinologist, head of obesity clinic, The Sheba Medical Center Institute of Endocrinology. “Our first groups of patients responded well to this brief, endoscopic procedure, and are achieving control of their diabetes while losing weight. It seems like EndoBarrier Therapy will become an integral part of our diabetes and obesity management program.”
In addition, GI Dynamics announced it has entered into an agreement with
Lavi - Medical Agencies (Lavi) as the exclusive distributor for EndoBarrier in Israel. EndoBarrier received medical device registration approval from the Israeli Ministry of Health in February 2012 for the treatment of type 2 diabetes and obesity for up to 12 months. It is also currently available in Australia, Chile and select countries in Europe.
“We are well known for our expertise in identifying high potential new and innovative technologies and bringing them to the local market,” said Dani Shaham, CEO of Lavi. “EndoBarrier Therapy enables diabetes control along with weight loss without the risks associated with bariatric surgery. We are excited to add EndoBarrier Therapy to our portfolio of innovative products and look forward to providing this novel treatment to the Israeli healthcare community.”
“Our first patient cases in Israel mark yet another milestone in the global commercialization of EndoBarrier Therapy,” said Mark C. Twyman, chief commercial officer, GI Dynamics. “Sheba Center is a highly accredited, national institution that is renowned for delivering exceptional healthcare in Israel, and we are delighted to be working with them. In the coming months, we will continue to cultivate and train additional centers in Israel and work closely with our distributor to provide EndoBarrier Therapy to the many patients living with uncontrolled type 2 diabetes and obesity.”